Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Bitdeer Technologies Group (BTDR) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Bitdeer Technologies GroupTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Bitdeer Technologies Group — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Bitdeer Technologies Group trades at $8.75 (market cap $2.12B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4.4× Bitdeer Technologies Group's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.

BIOBTDR
Market Cap
$9.39B$2.12B
Sector
HealthTechnology
52-Week High
$356.25$25.90
52-Week Low
$241.71$7.28
Enterprise Value
$9.14B$3.88B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Bitdeer Technologies Group

BTDR trades at $10.88, up 3.42% today, but remains under bearish technical pressure with recent earnings misses. Revenue grew to $620.25M in 2025, yet net income margin turned negative at -26.96% in 2026. The company secured a significant $4.7B AI data center deal, expanding beyond Bitcoin mining. Analyst consensus is strongly bullish with an 81.82% buy rating and a $22.71 price target, suggesting over 100% upside from current levels.

Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and negative cash flow. Risks include execution on new contracts and persistent earnings volatility. The stock offers speculative upside if operational improvements align with analyst optimism.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.

Read more on BTDR